TransEnterix to Feature Senhance™ Surgical Robot at ESGE Congress

TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it will exhibit and feature the Senhance Surgical Robot (“the Senhance” or “the Senhance system”) at the 25th Annual Congress of the European Society of Gynaecological Endoscopy (ESGE). The congress will be held on October 2-5, 2016 in Brussels, Belgium.
Dr. Salvatore Gueli Alletti, a gynecologic oncologist at the Gemelli
Hospital of the Catholic University of the Sacred Heart in Rome, Italy,
will give a lecture on the Senhance system. The lecture, titled,
“Initial clinical experience with a surgical robotic system
incorporating laparoscopic motion, force sensing instrumentation, and
eye-sensing camera control,” will be held on October 5, 2016, at 11:30am
CEST.
“With the Senhance, gynecologic applications have become one of the
leading procedural focuses for TransEnterix,” said Todd M. Pope,
President and CEO of TransEnterix.”Gynecologists are welcoming this new
robotic option with haptic force feedback, eye-sensing camera control,
and compelling procedural costs. We look forward to further showcasing
the Senhance’s unique features at this year’s congress.”
The Senhance will be available for surgeon evaluations at the congress.
The Senhance carries the CE Mark for use in general surgery, gynecology,
urology and thoracic surgery. TransEnterix is actively preparing a
submission for U.S. FDA Clearance for the Senhance.
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of
robotics to improve minimally invasive surgery by addressing the
clinical and economic challenges associated with current laparoscopic
and robotic options. The company is focused on the commercialization of
the Senhance Surgical Robotic System, a multi-port robotic system that
brings the advantages of robotic surgery to patients while enabling
surgeons with innovative technology such as haptic feedback and eye
sensing camera control. The company is also developing the SurgiBot™
System, a single-port, robotically enhanced laparoscopic surgical
platform. The Senhance Surgical Robotic System has been granted a CE
Mark but is not currently available for sale in the United States. For
more information, visit the TransEnterix website at www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to The Senhance™
Surgical Robotic System and the SurgiBot™ System and our current
regulatory and commercialization plans for these products. These
statements and other statements regarding our future plans and goals
constitute “forward looking statements” within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe harbor
from liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which may
cause results to differ materially from expectations, including whether
gynecologists are welcoming the new robotic option (of Senhance) with
haptic force feedback, eye-sensing camera control and compelling
procedural costs. For a discussion of the risks and uncertainties
associated with TransEnterix’s business, please review our filings with
the Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K filed on March 3, 2016 and our other filings we make
with the SEC. You are cautioned not to place undue reliance on these
forward looking statements, which are based on our expectations as of
the date of this press release and speak only as of the
origination date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.
[text ad]